Professor Shankar Balasubramanian knighted
Congratulations to Professor Shankar Balasubramanian who has been named a Knight Bachelor for services to science and medicine.
He co-invented next generation sequencing which has provided one of the most transformative changes in biology and medicine for several decades, and has led to the $1000 dollar human genome. He has also made important contributions to four-stranded DNA, known as G-quadruplexes, and their role in cancer. Professor Balasubramanian is Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College.
It is a great honour for me and a wonderful acknowledgement of the research that I have carried out in Cambridge with my co-workers and collaborators over the past two decades. I was particularly pleased to see recognition of our basic science and its impact on medicine, as I am jointly appointed between the Departments of Chemistry and Medicine.
– Professor Sir Shankar Balasubramanian, Cancer Research UK Cambridge Institute
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more